|
|
Article: Abraxis BioScience Reports 2009 Third Quarter Financial Results.(Financial report)
- Article from:
- Business Wire
- Article date:
- November 5, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Third Quarter Highlights:
* Sales of ABRAXANE([R]) Grows to $83 Million, Representing a 10 Percent Sequential Quarterly Increase
* The Independent Data Monitoring Committee for the ABRAXANE Non-Small Cell Lung Cancer Phase III Clinical Trial Has Recommended the Trial Proceed to Completion Without Changes to the Sample Size
* The FDA Has Granted ABRAXANE Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIb-IV Melanoma
* Pivotal Phase III Clinical Trials in Non-Small Cell Lung Cancer, Pancreatic Cancer and Melanoma Continue to Move Forward
LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully ...